EyePoint, Inc

EYPT.US
Healthcare · Biotechnology
11.96
-0.45 (-3.63%)
USD · NASDAQ

Company Information

Company Name
EyePoint, Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US30233G2093
CIK: 0001314102
CUSIP: 74439M107
Currency: USD
Full Time Employees: 214
Phone: 617 926 5000
Fiscal Year End: December
IPO Date: Jan 27, 2005
Description:

EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts.

Address:

480 Pleasant Street, Watertown, MA, United States, 02472

People

Directors & Officers

Name Title Year Born
Dr. Jay S. Duker M.D. President, CEO & Director 1959
Mr. George O. Elston CPA Executive VP & CFO 1965
Dr. Ramiro Ribeiro M.D., Ph.D. Chief Medical Officer 1983
Dr. Marcia Sellos-Moura Ph.D. Chief Scientific Officer NA
Mr. Ron I. Honig Esq. Chief Legal Officer & Company Secretary NA
Ms. Jennifer Leonard Chief People Officer & Senior VP of IT NA
Mr. David Scott Jones M.A. Senior Vice President 1968
Ms. Isabelle Lefebvre Chief Regulatory Officer NA
Mr. Michael J. Maciocio Chief Manufacturing Officer NA
Mr. Michael Campbell Chief Commercial Officer NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Apr 17, 2026 Ramiro Ribeiro N/A Sale 2.44K $15.00 $36.56K
Mar 16, 2026 Jay S Duker N/A Purchase 1.50K $13.15 $19.73K
Jan 05, 2026 Ramiro Ribeiro N/A Sale 42.54K $17.10 $727.50K

Shareholders

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Suvretta Capital Management, LLC 8.30M Mar 31, 2026 9.90% $2.73 5.99%
Cormorant Asset Management, LLC 8.27M Mar 31, 2026 9.86% $5.35 0.00%
BlackRock Inc 7.18M Mar 31, 2026 8.57% $0.00 5.74%
Federated Hermes Inc 5.67M Mar 31, 2026 6.77% $0.12 -5.78%
Franklin Resources Inc 5.05M Mar 31, 2026 6.02% $0.02 1.44%
Vanguard Group Inc 4.82M Dec 31, 2025 5.75% $0.00 27.08%
HHG PLC 3.60M Mar 31, 2026 4.30% $0.02 22.58%
Vanguard Capital Management, LLC 3.56M Mar 31, 2026 4.25% $0.00 0.00%
Adage Capital Partners Gp LLC 3.30M Mar 31, 2026 3.94% $0.07 -29.79%
Paradigm Biocapital Advisors LP 3.14M Mar 31, 2026 3.75% $0.83 -14.87%
COMMODORE CAPITAL LP 2.83M Mar 31, 2026 3.37% $2.11 0.00%
State Street Corp 2.10M Mar 31, 2026 2.50% $0.00 14.30%
Geode Capital Management, LLC 1.98M Mar 31, 2026 2.37% $0.00 4.44%
Citadel Advisors Llc 1.91M Mar 31, 2026 2.27% $0.00 0.00%
Aberdeen Group PLC 1.74M Mar 31, 2026 2.07% $0.04 8.24%
StemPoint Capital LP 1.62M Mar 31, 2026 1.94% $2.02 358.25%
Balyasny Asset Management LLC 1.44M Mar 31, 2026 1.72% $0.02 141.65%
Parkman Healthcare Partners LLC 1.35M Mar 31, 2026 1.62% $1.80 24.52%
Eventide Asset Management, LLC 1.25M Mar 31, 2026 1.49% $0.27 0.00%
Morgan Stanley - Brokerage Accounts 1.10M Mar 31, 2026 1.31% $0.00 389.99%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Federated Hermes Kaufmann R 2.77M 3.31% ▲ 0.00% Mar 31, 2026
2 Federated Hermes Kaufmann Growth 2.77M 3.31% ▲ 0.00% Mar 31, 2026
3 Vanguard Total Stock Mkt Idx Inv 2.64M 3.16% ▲ 1.65% Jun 30, 2026
4 iShares Russell 2000 ETF 2.03M 2.43% ▲ 0.60% Jun 30, 2026
5 Federated Hermes Kaufmann Small Cap Grow 1.98M 2.37% ▲ 0.00% Mar 31, 2026
6 Federated Hermes Kaufmann Small Cap A 1.98M 2.37% ▲ 0.00% Mar 31, 2026
7 Franklin Biotechnology Discv A(acc)USD 1.92M 2.29% ▲ 0.00% Jun 30, 2026
8 Franklin Small Cap Growth Adv 1.48M 1.77% ▲ 0.00% Jun 30, 2026
9 Franklin US Small Cap Growth Equity 1.48M 1.77% ▲ 2.61% Jun 30, 2026
10 Eventide Healthcare & Life Sciences I 1.25M 1.49% ▲ 0.00% Mar 31, 2026

Financial Highlights

Market Cap: $1.02B
EBITDA: $-279.38M
Book Value: $0.40
Earnings/Share: $-3.51
Profit Margin: 0.00%
Operating Margin: -450.66%
ROA (TTM): -54.13%
ROE (TTM): -102.71%
Revenue (TTM): $7.61M
Revenue/Share (TTM): $0.10
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 161.70%

Valuation Metrics

Enterprise Value: $838.16M
Trailing P/E: 0.00
Forward P/E: 6.16

Shares Statistics

Shares Outstanding: 83.84M
Shares Float: 70.47M
% Insiders: 368.40%
% Institutions: 11,195.40%
Short % Float: 20.65%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$31.37M
Cost of Goods Sold
adjust
$-2.07M
Gross Profit
subtotal
$29.31M
SG&A
adjust
$-51.61M
R&D
adjust
$-221.04M
Other Operating Expense
adjust
$-90.00K
Operating Income
subtotal
$-243.43M
Other / Non-Operating Items
adjust
$11.47M
Net Income
subtotal
$-231.96M

Earnings Per Share (EPS) History

Financial Ratios

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about EYPT.US!